The aim of this study was to evaluate the value of postoperative adjuvant therapy for resectable @entity1721 ( @entity1721 ) in China. We retrospectively analyzed 426 eligible @entity1 seen between October 2007 and November 2011. Specifically, we assessed clinicopathological characteristics and the disease-free and @entity1349 rates. Of the 426 @entity1 , 272 cases underwent surgery alone, and 154 cases received postoperative adjuvant therapy (67 cases with radiotherapy, 57 cases with chemotherapy, and 30 cases with simultaneous chemoradiotherapy). The median follow-up time was 48.0  months (23.0-72.0  months), and the median survival time was 48.4  months (1.0-72.0  months). We found a significant difference between the surgery-alone and adjuvant therapy groups in the status of lymph node (LN) @entity3 (N stage; P  <  0.01), but there were no differences between the two groups with regard to other clinicopathological characteristics, including age, sex, lesion location, T stage, differentiation grades, surgery approach, or average number of LN dissections. The 5-year disease-free survival (DFS) rates of the surgery-alone and adjuvant therapy groups were 48.9 and 37.1  %, respectively (P  <  0.001); no significant difference was found in 5-year @entity1349 ( @entity1349 ) rate between the two groups (P  >  0.05). A stratification analysis based on N stage suggested that the 5-year DFS and @entity1349 rates were similar in N0-N3 subgroups (P  >  0.05), except that @entity1 with surgery alone had a higher 5-year DFS than those with postoperative adjuvant therapy in N0 subgroup (P  =  0.013). Our data suggest that @entity1 with resectable thoracic @entity1721 may not benefit from postoperative adjuvant therapy. Further prospective studies are required to elucidate the utility of postoperative adjuvant therapy and to standardize individualized treatments for resectable @entity1721 .

Postoperative adjuvant therapy for resectable XXXX : a retrospective analysis of 426 cases.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity1721 :: ('MESH:C562729', 'Disease') :: ['thoracic esophageal squamous cell carcinoma', 'ESCC'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1721 :: (MESH:C562729,Disease) :: ['thoracic esophageal squamous cell carcinoma']
